2021
Limited benefit and high financial burden of drugs used to manage cancer-associated anorexia/cachexia syndrome (CACS).
Gupta A, Nshuti L, Grewal U, Sedhom R, Parsons H, Blaes A, Virnig B, Lustberg M, Subbiah I, Nipp R, Dy S, Dusetzina S. Limited benefit and high financial burden of drugs used to manage cancer-associated anorexia/cachexia syndrome (CACS). Journal Of Clinical Oncology 2021, 39: 55-55. DOI: 10.1200/jco.2020.39.28_suppl.55.Peer-Reviewed Original ResearchPrescription drug coverageAnorexia/cachexia syndromeDrug coveragePocket costsRisk/benefit ratioPatient-clinician discussionsSupportive care guidelinesFinancial burdenList of drugsCost of drugsUse of drugsHigh financial burdenEnd of lifeCachexia syndromeCare guidelinesUnwanted side effectsGeneric olanzapineSide effectsClinical practiceCertain drugsMultiple drugsStudy authorsBenefit ratioDrugsLimited benefit
2019
Double‐Blind Placebo‐Controlled Trial of Galantamine for Methadone‐Maintained Individuals With Cocaine Use Disorder: Secondary Analysis of Effects on Illicit Opioid Use
Carroll KM, DeVito EE, Yip SW, Nich C, Sofuoglu M. Double‐Blind Placebo‐Controlled Trial of Galantamine for Methadone‐Maintained Individuals With Cocaine Use Disorder: Secondary Analysis of Effects on Illicit Opioid Use. American Journal On Addictions 2019, 28: 238-245. PMID: 31165574, PMCID: PMC9078084, DOI: 10.1111/ajad.12904.Peer-Reviewed Original ResearchConceptsMethadone-maintained individualsOpioid useSecondary analysisMultiple drugsConcurrent cocaine dependenceTrial of galantaminePlacebo-controlled trialDouble-blind placeboIllicit opioid useRandomized clinical trialsCocaine use disorderGalantamine's effectFuture trialsClinical trialsUrine specimenUrine specimensUse disordersOpioidsCholinesterase inhibitorsMaintenance settingCocaine useCocaine dependencePlaceboConcurrent useGalantamine
2014
Chapter 7 Drug Resistance and Drug Synergism
Silverman R, Holladay M. Chapter 7 Drug Resistance and Drug Synergism. 2014, 333-356. DOI: 10.1016/b978-0-12-382030-3.00007-6.Peer-Reviewed Original ResearchDrug synergismReversibility of drug actionDrug actionInhibition of multiple pathwaysEfflux pump inhibitionImproved therapeutic effectMechanisms of resistanceSite of actionPump inhibitionDrug resistanceMultiple drugsTherapeutic effectTarget proteinsProdrug activationDrugDrug targetsDrug distributionMultiple pathwaysInhibition
2012
Pathogenesis in tuberculosis: transcriptomic approaches to unraveling virulence mechanisms and finding new drug targets
Mukhopadhyay S, Nair S, Ghosh S. Pathogenesis in tuberculosis: transcriptomic approaches to unraveling virulence mechanisms and finding new drug targets. FEMS Microbiology Reviews 2012, 36: 463-485. PMID: 22092372, DOI: 10.1111/j.1574-6976.2011.00302.x.Peer-Reviewed Original ResearchConceptsMajor health problemHost immune responseEmergence of strainsDrug targetsDendritic cellsEffective drug targetsInhibition of apoptosisImmune responseNew drug targetsHealth problemsLipid metabolismMultiple drugsTuberculosisComplex etiologyMycobacterium tuberculosisIntracellular life styleTranscriptome signaturesVirulence mechanismsGenome-wide expression profilingDrugsAntibiotic drugsExpression profilingProtein secretionLife stylePoor understanding
2011
Bayesian methods for fitting mixture models that characterize branching tree processes: An application to development of resistant TB strains
Izu A, Cohen T, Mitnick C, Murray M, De Gruttola V. Bayesian methods for fitting mixture models that characterize branching tree processes: An application to development of resistant TB strains. Statistics In Medicine 2011, 30: 2708-2720. PMID: 21717491, PMCID: PMC3219798, DOI: 10.1002/sim.4287.Peer-Reviewed Original ResearchConceptsCharacterization of uncertaintyBayesian approachBayesian methodsBranching tree modelStatistical methodsMixture modelBranching treeNatural wayPrior informationDrug resistance-conferring mutationsSuch cross-sectional dataDrug-resistant TBResistant TB strainsCombination of antibioticsDrug resistance mutationsMeasurement errorResistance-conferring mutationsTB strainsSingle patientTreatment policyPatientsMultiple drugsDiagnostic specimensCross-sectional dataGenetic mutations
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply